Great Novel Therapeutics Biotech & Medicals (TPEX: 7427)
Health Care · Biotechnology · TW
NT$73.00
+1.53% today · +116.9% 1Y
Great Novel Therapeutics Biotech & Medicals (TPEX: 7427) operates in the Biotechnology industry within the Health Care sector. The company is valued at $97.65M and employs 22 people.
Over the last twelve months the share price has gained 116.9%, trading between 29.25 and 82.80.
Tweenvest scores Great Novel Therapeutics Biotech & Medicals across four factors: quality 32/100. Its strongest factor is quality.
7427 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $97.65M
- Revenue (TTM)
- $195.13K
- P/E
- —
- EPS
- -2.52
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- NT$82.80
- 52-week low
- NT$29.25
- Avg volume (3M)
- —
- Shares outstanding
- 42.59M
- Employees
- 22
- Next earnings
- —
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals specializes in crafting pharmaceutical solutions to combat advanced and treatment-resistant cancers. Their primary focus lies in the realm of cancer immunotherapy, encompassing the creation of compounds such as tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was previously known as GNT Biotech & Medicals Corporation. Established in 2013, its headquarters are situated in Taipei City, Taiwan.
- ISIN
- TW0007427007
- Founded
- 2013
- Listed since
- Jul 8, 2021
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.